Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 31Myeloid 11Lymphoid 4Dermatologic 4Gastrointestinal 3Thoracic 2Other solid neoplasm 2Genitourinary 2Classical hematology 2Breast 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Decitabine × Breast × Clear all
NCT03295552 2022-04-06

DETECT

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated
12 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01194908 2015-01-26

Re-expression of ER in Triple Negative Breast Cancers

Emory University

Phase 1/2 Terminated
5 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡